文献速递慢性肾脏病血液净化与透析水电解质与酸碱

NPT-IIb抑制剂ASP3325未能改善CKD高磷血症

NPT-IIb Inhibition Does Not Improve Hyperphosphatemia in CKD.
PubMed 文献 · Kidney Int Rep · 2017-08-12

该研究在健康受试者中开展随机双盲安慰剂对照的1a期单次和多次递增剂量试验,并在高磷血症血液透析ESRD患者中开展开放标签1b期试验,评估NPT-IIb抑制剂ASP3325的疗效与安全性。结果显示ASP3325未改变健康人尿磷或粪磷排泄,也未降低ESRD患者血清磷水平,但安全性和耐受性良好。

要点

  • ASP3325在健康受试者中未引起尿磷或粪磷排泄的时间或剂量依赖性变化。
  • 在ESRD血液透析患者中,ASP3325每日三次给药两周未降低血清磷水平。
  • ASP3325在健康受试者和ESRD患者中均安全且耐受性良好。

核心结论

  • NPT-IIb抑制剂ASP3325在ESRD患者中未能有效降低血清磷水平。
  • NPT-IIb在人体中的相关性及口服NPT-IIb抑制剂治疗ESRD高磷血症的可行性仍不确定。

研究设计与样本

  • 随机双盲安慰剂对照1a期单次递增剂量研究纳入健康受试者88例。
  • 随机双盲安慰剂对照1a期多次递增剂量研究纳入健康受试者36例。
  • 随机开放标签非对照1b期研究纳入血液透析高磷血症ESRD患者,单次口服给药5例,多次口服给药17例。

主要发现

  • 健康受试者接受单次或多次ASP3325给药7天后,尿磷或粪磷排泄未出现时间或剂量依赖性变化。
  • ESRD患者餐前或餐后每日三次给予ASP3325两周,血清磷水平未降低。
  • ASP3325在健康受试者和ESRD患者中均安全且耐受性良好。

关键数值与推荐

  • 健康受试者主要疗效指标为尿磷和粪磷排泄。
  • ESRD患者主要疗效指标为血清磷水平。

临床怎么用

  • 本研究结果不支持使用ASP3325通过抑制NPT-IIb来降低ESRD患者血清磷水平。

局限性

  • NPT-IIb抑制在人体中降低血清磷的有效性仍需进一步研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Serum phosphate levels are insufficiently controlled in many patients with end-stage renal disease (ESRD), and novel therapeutic strategies are needed. Blocking intestinal phosphate absorption mediated by sodium-dependent phosphate co-transporter type 2b (NPT-IIb) holds promise; thus, we evaluated the efficacy, safety, tolerability, and pharmacokinetics of the novel and specific small molecule NPT-IIb inhibitor ASP3325 for the first time in humans. METHODS: We conducted a randomized, double-blind, placebo-controlled, phase 1a single (n = 88) and multiple (n = 36) ascending dose study in healthy subjects, and a randomized, open-label, uncontrolled, phase 1b study in hyperphosphatemic ESRD patients on hemodialysis (single oral dose, n = 5; multiple oral doses, n = 17). Primary efficacy measures were urinary phosphate and fecal phosphorous excretion (healthy subjects) and serum phosphate level (ESRD patients). RESULTS: No time- or dose-dependent changes in urinary phosphate or fecal phosphorous excretion were observed following single/multiple ASP3325 doses for 7 days in healthy subjects. In ESRD patients, ASP3325 administered 3 times daily for 2 weeks before or after a meal did not reduce serum phosphate levels. ASP3325 was safe and well tolerated in both populations. CONCLUSION: NPT-IIb inhibition with ASP3325 was not effective in reducing serum phosphate levels in ESRD patients. The relevance of NPT-IIb in humans and feasibility of oral NPT-IIb inhibitors for treatment of hyperphosphatemia in ESRD remain uncertain.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Larsson TE, Kameoka C, Nakajo I, et al. NPT-IIb Inhibition Does Not Improve Hyperphosphatemia in CKD. Kidney Int Rep. 2017. PMID: 29340316. doi:10.1016/j.ekir.2017.08.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。